This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2002;287:2936.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved secretin (SecreFlo, Chesapeake Biological Laboratories, Baltimore), a synthetic formulation of the naturally occurring porcine hormone (no longer available for clinical use) for the following uses: (1) as a diagnostic test of exocrine pancreatic function. Normal response to secretin administration is volume output greater than 2.0 mL/Kg/h, and bicarbonate concentration greater than 80 mmol/L; and (2) as a test to aid in diagnosis of gastrinoma. In the absence of gastrinoma, serum gastrin levels change minimally or not at all in response to secretin.

Approval was based on results of seven clinical trials. In two studies, SecreFlo was administered to a total of 12 normal volunteers, eight patients with chronic pancreatitis, and four patients with history of chronic pancreatitis following recovery of pancreatic function. After administration, all 12 normal volunteers and the four patients whose pancreatic function had recovered had peak concentration of bicarbonate above 80 mEq/L, while . . . [Full Text of this Article]